Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
FDA rejects Summit’s PD-1xVEGF ivonescimab in NSCLC
Ivonescimab’s setback has narrowed its potential first-mover advantage as several pharma giants race to advance their own PD-(L)1xVEGF bispecifics.
Angus Liu
Nov 15, 2026 7:50am
ESMO: AZ, Hutchmed’s Orpathys combo shows post-Tagrisso power
Oct 25, 2026 11:30am
Merck’s sac-TMT posts major PFS benefit in PD-L1-negative NSCLC
Oct 25, 2026 5:15am
Increased deaths shadow Enhertu’s first-line lung cancer data
Sep 13, 2026 7:00pm
GSK prepares frontline FDA bid for lung cancer drug Jideytro
Sep 13, 2026 7:00pm
Ivonescimab tops Keytruda with strong OS in PD-L1-high NSCLC
Sep 13, 2026 8:00am
